Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus

Background Tacrolimus (TAC) is an immunosuppressive macrolide that blocks T-cell activation by specifically inhibiting calcineurin. TAC was approved in Japan for the treatment of rheumatoid arthritis (RA) in 2005. However, the safety and effectiveness of TAC adding on to biological disease-modifying...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs in R&D 2015-12, Vol.15 (4), p.307-317
Hauptverfasser:	Ishida, Kota, Shiraki, Katsuhisa, Yoshiyasu, Takashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Drug Resistance - drug effects Drug Therapy, Combination Female Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Internal Medicine Male Medicine Medicine & Public Health Middle Aged Original Original Research Article Pharmacology/Toxicology Pharmacotherapy Product Surveillance, Postmarketing - statistics & numerical data Tacrolimus - adverse effects Tacrolimus - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!